Bristol-Myers Squibb Co vs VF Corp — how do they compare? Bristol-Myers Squibb Co trades at $63.41 (market cap $129.94B), while VF Corp trades at $14.9 (market cap $5.81B). The key difference: Bristol-Myers Squibb Co is far larger — about 22.4× VF Corp's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | VFC | |
|---|---|---|
Market Cap | $129.94B | $5.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $21.55 |
52-Week Low | $42.60 | $12.21 |
Enterprise Value | $163.92B | $10.09B |
Dividend Yield | 3.96% | 2.44% |
Trailing returns across standard periods
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →